المؤلفون: Gunter Wolf, Michael Kiehntopf, Christine Hamann, Lorenz C. Hofbauer, Sybille Franke, Sabine Lodes, Thomas Neumann, Alexander Sämann, Martina Rauner, Thomas Lehmann, Ulrich A. Müller, Bettina Kästner

المصدر: Clinical Endocrinology. 80:649-655

مصطلحات موضوعية: Adult, Genetic Markers, Male, medicine.medical_specialty, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Parathyroid hormone, Body Mass Index, Bone remodeling, Young Adult, chemistry.chemical_compound, Sex Factors, Endocrinology, Bone Density, Internal medicine, Vitamin D and neurology, Humans, Medicine, Adaptor Proteins, Signal Transducing, Aged, Femoral neck, Bone mineral, Type 1 diabetes, business.industry, nutritional and metabolic diseases, Middle Aged, medicine.disease, Cross-Sectional Studies, medicine.anatomical_structure, Diabetes Mellitus, Type 2, chemistry, Case-Control Studies, Bone Morphogenetic Proteins, Body Composition, Sclerostin, Female, business, Body mass index, Biomarkers, Glomerular Filtration Rate

الوصف: SummaryAim Type 1 diabetes mellitus (T1DM) increases fragility fractures due to low bone mass, micro-architectural alterations and decreased bone formation. Sclerostin is expressed by osteocytes and inhibits osteoblastic bone formation. We evaluated serum sclerostin levels in T1DM and their association with bone mineral density (BMD), bone turnover, glycaemic control and physical activity. Patients and Methods In a cross-sectional study, 128 men and premenopausal women with long-standing T1DM (mean age 43·4 ± 8·8 years, diabetes duration 22·4 ± 9·5 years) and 77 age-, BMI (Body Mass Index) and gender-matched healthy individuals were evaluated. Results Serum sclerostin levels were higher in T1DM compared with controls, irrespective of gender (male 0·55 ± 0·17 vs 0·49 ± 0·12 ng/ml, P = 0·046; female 0·52 ± 0·19 ng/ml vs 0·43 ± 0·12 ng/ml, P = 0·012). Partial correlation analysis adjusted for age and gender revealed a positive correlation between serum sclerostin levels and BMD at lumbar spine and femoral neck in T1DM and between BMD at lumbar spine, femoral neck and total hip in controls. Bone turnover markers, parathyroid hormone, calcium and vitamin D did not correlate with serum sclerostin levels in T1DM or controls. Physical activity was not associated with serum sclerostin levels. A multivariate analysis revealed that only the interaction of T1DM and age affects serum sclerostin levels but not T1DM alone. The influence of age on serum sclerostin levels was more pronounced in T1DM compared with controls. Conclusions Sclerostin serum levels were increased in patients with T1DM, and the positive correlation of age with serum sclerostin levels was stronger in T1DM. There was no effect of serum sclerostin levels on markers of bone metabolism and they do not explain the detrimental effects of T1DM on BMD.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65e0764166789191e1ebb25229bbd012Test
https://doi.org/10.1111/cen.12364Test

المؤلفون: Nigel K. Stepto, Cheryce L. Harrison, Samantha Cassar, Lisa J. Moran, Anju E. Joham, Helena J. Teede

المصدر: Clinical endocrinology. 83(1)

مصطلحات موضوعية: Adult, Leptin, medicine.medical_specialty, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Gastric Inhibitory Polypeptide, Overweight, Young Adult, Endocrinology, Insulin resistance, Glucagon-Like Peptide 1, Predictive Value of Tests, Internal medicine, Diabetes mellitus, Plasminogen Activator Inhibitor 1, Medicine, Humans, Resistin, Nicotinamide Phosphoribosyltransferase, C-Peptide, business.industry, nutritional and metabolic diseases, Glucose clamp technique, medicine.disease, Polycystic ovary, female genital diseases and pregnancy complications, Ghrelin, Cross-Sectional Studies, Case-Control Studies, Glucose Clamp Technique, Biomarker (medicine), Cytokines, Female, medicine.symptom, Insulin Resistance, business, Biomarkers, Polycystic Ovary Syndrome

الوصف: SummaryObjective Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with metabolic complications. Metabolic biomarkers with roles in obesity, glycaemic control and lipid metabolism are potentially relevant in PCOS. The aim was to investigate metabolic biomarkers in lean and overweight women with and without PCOS and to determine whether any biomarker was able to predict insulin resistance in PCOS. Design Cross-sectional study. Patients Eighty-four women (22 overweight and 22 lean women with PCOS, 18 overweight and 22 lean women without PCOS) were recruited from the community and categorized based on PCOS and BMI status. Measurements Primary outcomes were metabolic biomarkers [ghrelin, resistin, visfatin, glucagon-like peptide-1 (GLP-1), leptin, plasminogen activator inhibitor -1 (PAI-1), glucose-dependent insulinotropic polypeptide (GIP) and C-Peptide] measured using the Bio-Plex Pro Diabetes assay and insulin sensitivity as assessed by glucose infusion rate on euglycaemic–hyperinsulinaemic clamp. Results The biomarkers C-peptide, leptin, ghrelin and visfatin were different between overweight and lean women, irrespective of PCOS status. The concentration of circulating biomarkers did not differ between women with PCOS diagnosed by the Rotterdam criteria or National Institute of Health criteria. PAI-1 was the only biomarker that significantly predicted insulin resistance in both control women (P = 0·04) and women with PCOS (P = 0·01). Conclusions Biomarkers associated with metabolic diseases appear more strongly associated with obesity rather than PCOS status. PAI-1 may also be a novel independent biomarker and predictor of insulin resistance in women with and without PCOS.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::016bdabea70640185fc199151f04739bTest
https://pubmed.ncbi.nlm.nih.gov/25369111Test

المؤلفون: Maddalena Peracchi, Giovanni Faglia, Paolo Beck-Peccoz, Anna Spada, Alessandro Pizzocaro, Sabrina Corbetta

المصدر: Scopus-Elsevier

مصطلحات موضوعية: Adenoma, Adult, Male, medicine.medical_specialty, Pituitary gland, endocrine system diseases, Adolescent, Endocrinology, Diabetes and Metabolism, Pancreatic Polypeptide, Phosphates, Endocrinology, Pituitary adenoma, Internal medicine, Gastrins, medicine, Multiple Endocrine Neoplasia Type 1, Prevalence, Humans, Pituitary Neoplasms, Prolactinoma, Multiple endocrine neoplasia, Aged, Hyperparathyroidism, Gastrinoma, business.industry, Middle Aged, medicine.disease, medicine.anatomical_structure, Parathyroid Hormone, Calcium, Female, business, Somatostatin, Primary hyperparathyroidism, Biomarkers, Vasoactive Intestinal Peptide

الوصف: OBJECTIVE We have investigated the prevalence of MEN 1 in patients with recognized pituitary adenomas. Since hyperparathyroidism is present in nearly 95–100% of patients with MEN 1 and frequently is the first condition to be identified, the study was limited to the identification of patients with hyperparathyroidism while the screening for gastroenteropancreatic (GEP) lesions was carried out in patients with both pituitary and parathyroid lesions. PATIENTS AND MEASUREMENTS Serum total and ionized calcium, phosphate and intact PTH 1-84 (EASIA) were measured in 166 patients (68 with non-functioning pituitary adenoma, 42 with prolactinoma, 35 with GH-secreting adenoma, 17-with ACTH-screening adenoma, 1 with TSH-secreting adenoma, 1 with FSH-secreting adenoma and 2 with an only α-subunit secreting adenoma) referred to our clinic from 1990 to 1996. Plasma gastrin, somatostatin, pancreatic polypeptide and vasoactive intestinal peptide were measured by RIA in patients with hyperparathyroidism. RESULTS Eight of 166 patients (4.8%) were found to have primary hyperparathyroidism and among these 2 also had a gastrinoma while there was no evidence of other GEP tumours. Considering the tumour type, 6 had prolactinoma (14.3%), 1 GH-secreting adenoma (2.8%) and 1 non-functioning adenoma (1.5%). In most patients the diagnosis of pituitary tumour was made several years before that of hyperparathyroidism (from 1 to 15 years) although 6 patients had previously suffered from urolithiasis and one had undergone gastric resections for recurrent peptic ulcers. One patient was identified as a MEN 1 gene carrier and 2 had relatives with signs and symptoms referable to parathyroid or GEP lesions. CONCLUSIONS The study shows a prevalence of 4.8% of primary hyperparathyroidism in unselected patients with known pituitary tumours similar to that reported in a previous study. By contrast, the prevalence of MEN 1 in patients with prolactinoma was definitely high (14.3%). In most patients the diagnosis of pituitary tumours was made several years before that of hyperparathyroidism. Although the patients were believed to harbour a sporadic pituitary tumour, most of them had had signs and/or symptoms referable to one or both of the other organs involved in MEN 1, often concomitantly with those of pituitary tumours. These data indicate that the diagnosis of MEN 1 syndrome is missed in a substantial proportion of patients with prolactinomas and therefore the screening of these patients for the syndrome is strongly recommended.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::321efd33eb6152057960aee07cf92d12Test
https://pubmed.ncbi.nlm.nih.gov/10396374Test